Role of hematopoietic prostaglandin D synthase in biphasic nasal obstruction in guinea pig model of experimental allergic rhinitis

Kajiwara, Daisuke; Aoyagi, Hiroki; Shigeno, Kazuhiko; Togawa, Michinori; Tanaka, Katsunao; Inagaki, Nobuya; Miyoshi, Kazuhisa

doi:10.1016/j.ejphar.2011.05.041

Cited by 16 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nsal congestion was not evaluated in the current study. However, the PGDS, associated with induction of late-phase nasal blockage ( 34 , 35 ), exhibited markedly decreased mRNA expression levels in the nasal mucosa following IB treatment. Whether the IB-induced decrease in PGDS, and even subsequent PGD2 production, improved nasal obstruction requires further investigation.…”

Section: Discussionmentioning

confidence: 99%

Effects of anticholinergic agent on miRNA profiles and transcriptomes in a murine model of allergic rhinitis

Hou

Xie

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Anticholinergic agent, ipratropium bromide (IB) ameliorates symptoms of allergic rhinitis (AR) using neuroimmunologic mechanisms. However, the underlying molecular mechanism remains largely unclear. In the present study, 27 mice with AR induced by ovalbumin were randomly allocated to one of three groups: Model group, model group with IB treatment for 2 weeks, and model group with IB treatment for 4 weeks. Allergic symptoms were evaluated according to symptoms scores. Differentially expressed genes [microRNAs (miRNAs) and messenger RNAs (mRNAs)] of nasal mucosa were identified by microarray analysis. The expression levels of candidate genes were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The data indicates that the symptoms scores in allergic mice were significantly reduced by IB treatment. In the nasal mucosa of allergic mice with IB treatment, 207 mRNAs and 87 miRNAs were differentially expressed, when compared with the sham group. IB treatment significantly downregulated the expression levels of interleukin-4Rα and prostaglandin D2 synthase, whereas the leukemia inhibitory factor, A20 and nuclear receptor subfamily 4, group A, member 1 expression levels were upregulated. Similarly, the expression levels of mmu-miR-124-3p/5p, −133b-5p, −133a-3p/5p, −384-3p, −181a-5p, −378a-5p and −3071-5p were significantly increased. RT-qPCR data further validated these mRNA and miRNA expression levels. Thus, IB treatment regulated expression of allergic immune-associated mRNAs and miRNAs of the nasal mucosa in allergic mice, which may be associated with ameliorated nasal allergic symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of anticholinergic agent on miRNA profiles and transcriptomes in a murine model of allergic rhinitis

Hou

Xie

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Although previous studies have shown that selective inhibition of H-PGDS (TFC-007 and TAS-204) is effective in reducing nasal blockage and eosinophil infiltration in animal models of allergic rhinitis, no studies have yet been conducted in humans to determine the role of H-PGDS inhibitors in allergic rhinitis [179,180].…”

Section: Allergic Rhinitismentioning

confidence: 99%

The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy

Lee

Kim

2020

IJMS

View full text Add to dashboard Cite

Prostaglandins (PGs) are a family of lipid compounds that are derived from arachidonic acid via the cyclooxygenase pathway, and consist of PGD 2 , PGI 2 , PGE 2 , PGF 2 , and thromboxane B 2 . PGs signal through G-protein coupled receptors, and individual PGs affect allergic inflammation through different mechanisms according to the receptors with which they are associated. In this review article, we have focused on the metabolism of the cyclooxygenase pathway, and the distinct biological effect of each PG type on various cell types involved in allergic airway diseases, including asthma, allergic rhinitis, nasal polyposis, and aspirin-exacerbated respiratory disease.

show abstract

“…In allergic rhinitis, hPGDS but not LPGDS expression could be detected in the nasal mucosa, while various hPGDS expressing infiltrating cells were identified [43]. Blockade of hPGDS function by treatment of antigen-challenged guinea pigs with hPGDS inhibitor TAS-204 or TFC-007 suppressed nasal blockage, nasal airway resistance and eosinophil infiltration [119,120]. Treatment with hPGDS inhibitor HQL-79 suppressed OVA-induced allergic airway inflammation in wild types and also in mice overexpressing human hPGDS [28].…”

Section: Pgd2 Signaling As Therapeutic Target In Allergic Diseasesmentioning

confidence: 99%

Therapeutic Potential of Hematopoietic Prostaglandin D2 Synthase in Allergic Inflammation

Rittchen

Heinemann

2019

Cells

View full text Add to dashboard Cite

Worldwide, there is a rise in the prevalence of allergic diseases, and novel efficient therapeutic approaches are still needed to alleviate disease burden. Prostaglandin D2 (PGD2) has emerged as a central inflammatory lipid mediator associated with increased migration, activation and survival of leukocytes in various allergy-associated disorders. In the periphery, the hematopoietic PGD synthase (hPGDS) acts downstream of the arachidonic acid/COX pathway catalysing the isomerisation of PGH2 to PGD2, which makes it an interesting target to treat allergic inflammation. Although much effort has been put into developing efficient hPGDS inhibitors, no compound has made it to the market yet, which indicates that more light needs to be shed on potential PGD2 sources and targets to determine which particular condition and patient will benefit most and thereby improve therapeutic efficacy. In this review, we want to revisit current knowledge about hPGDS function, expression in allergy-associated cell types and their contribution to PGD2 levels as well as beneficial effects of hPGDS inhibition in allergic asthma, rhinitis, atopic dermatitis, food allergy, gastrointestinal allergic disorders and anaphylaxis.

show abstract

Role of hematopoietic prostaglandin D synthase in biphasic nasal obstruction in guinea pig model of experimental allergic rhinitis

Cited by 16 publications

References 29 publications

Effects of anticholinergic agent on miRNA profiles and transcriptomes in a murine model of allergic rhinitis

Effects of anticholinergic agent on miRNA profiles and transcriptomes in a murine model of allergic rhinitis

The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy

Therapeutic Potential of Hematopoietic Prostaglandin D2 Synthase in Allergic Inflammation

Contact Info

Product

Resources

About